Papilloma viruses, agents for detecting them and for treating diseases caused by such viruses

ABSTRACT

This invention relates to a DNA coding for a peptide of a papilloma virus major capsid protein. Moreover, this invention deals with a papilloma virus genome containing such a DNA. Furthermore, this invention concerns proteins coded by the papilloma virus genome and virus-like particles as well as antibodies directed thereagainst and the use thereof for diagnosis, treatment and vaccination.

This is a national phase filing of the Application No. PCT/DE96/01369, which was filed with the Patent Corporation Treaty on Jul. 19, 1996. and is entitled to priority of the German Patent Application P 195 26 386.3. filed Jul. 19, 1995.

FIELD OF THE INVENTION

This invention relates to a DNA coding for a peptide of a papilloma virus major capsid protein. Moreover, this invention deals with a papilloma virus genome containing such a DNA. In addition, this invention concerns proteins coded by the papilloma virus genome and virus-like particles as well as antibodies directed against them and their use for diagnosis, treatment and vaccination.

BACKGROUND OF THE INVENTION

It is known that papilloma viruses infect the epithelium of human beings and animals. Human papilloma viruses (hereinafter referred to as HP viruses) are found in benign epithelial neoplasms, e.g. warts, condylomas in the genital zone, and malignant epithelial neoplasms, e.g. carcinomas of the skin and the uterus. Zur Hausen, 1989, Cancer Research 49: 4677-4681. HP viruses are also considered for the growth of malignant tumors in the respiratory tract. Zur Hausen, 1976, Cancer Research 36: 530. Besides, HP viruses are considered at least jointly responsible for the growth of squamous carcinomas of the lung. Syrjänen, 1980, Lung 158: 131-142.

Papilloma viruses have an icosahedral capsid without envelope in which a circular, double-stranded DNA molecule of about 7900 bp is present. The capsid comprises a major capsid protein (L1) and a minor capsid protein (L2). Both proteins coexpressed or L1 expressed alone, result in vitro in the formation of virus-like particles Kirnbauer et al., 1993. Journal of Virology 67:6929-6936.

Papilloma viruses cannot be proliferated in monolayer cell culture. Therefore, their characterization is extremely difficult, the detection of papilloma viruses already creating considerable problems. This applies especially to papilloma viruses in carcinomas of the skin. A reliable detection thereof and thus well-calculated steps taken thereagainst are not possible by now.

Thus, it is the object of the present invention to provide a product by which papilloma viruses can be detected, particularly in carcinomas of the skin. Furthermore, a product should be provided to be able to take therapeutic steps against these papilloma viruses.

SUMMARY OF THE INVENTION

This invention relates to a DNA coding for a peptide of a papilloma virus major capsid protein. Moreover, this invention deals with a papilloma virus genome containing such a DNA. Furthermore, this invention concerns proteins coded by the papilloma virus genome and virus-like particles as well as antibodies directed thereagainst and the use thereof for diagnosis treatment and vaccination.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the base sequence and the amino acid sequence, derived therefrom, of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid VS19-6 with DSM (Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSM 10104 on Jul. 11, 1995.

FIG. 2 shows the base sequence and the amino acid sequence, derived therefrom, of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid VS200-1 with DSM under DSM 10096 on Jul. 11, 1995.

FIG. 3 shows the base sequence and the amino acid sequence, derived therefrom, of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid VS201-1 with DSM under DSM 10097 on Jul. 11, 1995.

FIG. 4 shows the base sequence and the amino acid sequence, derived therefrom, of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid VS202-8 with DSM under DSM 10098 on Jul. 11, 1995.

FIG. 5 shows the base sequence and the amino acid sequence, derived therefrom, of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid VS203-2 with DSM under DSM 10099 on Jul. 11, 1995.

FIG. 6 shows the base sequence and the amino acid sequence, derived therefrom, of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid VS204-4 with DSM under DSM 10100 on Jul. 11, 1995.

FIG. 7 shows the base sequence and the amino acid sequence, derived therefrom, of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid VS205-1 with DSM under DSM 10101 on Jul. 11, 1995.

FIG. 8 shows the base sequence and the amino acid sequence, derived therefrom, of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid VS206-2 with DSM under DSM 10109 on Jul. 13, 1995.

FIG. 9 shows the base sequence and the amino acid sequence, derived therefrom, of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid VS207-22 with DSM under DSM 10102 on Jul. 11, 1995.

FIG. 10 shows the base sequence and the amino acid sequence, derived therefrom, of a DNA coding for a peptide of L1 of a papilloma virus. This DNA was deposited as plasmid VS208-1 with DSM under DSM 10103 on Jul. 11, 1995.

DETAILED DESCRIPTION OF THE INVENTION

It is the object of the present invention to provide a product by which papilloma viruses can be detected, particularly in carcinomas of the skin. Furthermore, a product is provided which enables to take therapeutic steps against these papilloma viruses.

Accordingly, the subject matter of the invention relates to a DNA coding for a peptide of a papilloma virus major capsid protein (L1), the peptide comprising the amino acid sequence of FIG. 1, FIG. 2, FIG. 3, FIG. 4, FIG. 5, FIG. 6, FIG. 7, FIG. 8, FIG. 9 or FIG. 10 or an amino acid sequence differing: therefrom by one or more amino acids.

A further subject matter of the invention relates to a DNA coding for a peptide of a papilloma virus major capsid protein, the DNA comprising the base sequence of FIG. 1, FIG. 2, FIG. 3, FIG. 4, FIG. 5, FIG. 6, FIG. 7, FIG. 8, FIG. 9 or FIG. 10 or a base sequence differing therefrom by one or more base pairs.

The above DNA has the following sequence homology with respect to known papilloma viruses:

DNA of FIG. 1: 69.1% with respect to HP virus 65

DNA of FIG. 2: 80.7% with respect to HP virus 24

DNA of FIG. 3: 69.4% with respect to HP virus 48

DNA of FIG. 4: 66.3 % with respect to HIP virus 48

DNA of FIG. 5: 66.9% with respect to HP virus 65

DNA of FIG. 6: 66.4% with respect to HP virus 65

DNA of FIG. 7: 69.1% with respect to HP virus 4

DNA of FIG. 8: 68.7% with respect to HP virus 48

DNA of FIG. 9: 76.6% with respect to HP virus 48

DNA of FIG. 10: 81.8% with respect to HP virus 68

According to the invention, the above DNA can be present in a vector and expression vector, respectively. A person skilled in the art is familiar with examples thereof. In the case of an expression vector for E. coli, these are e.g. pGEMEX, pUC derivatives, pGEM-T and pGEX-2T. For the expression in yeast e.g. pY00 and Ycpad1 have to be mentioned, while for the expression in animal cells e.g. pKCR, pEF-BOS, cDM8 and pCEV4 have to be indicated.

The person skilled in the art knows suitable cells to express the above DNA present in an expression vector. Examples of such cells comprise the E. Coli strains HB101, DH1, ×776, JM101, JM 109, and XL1-Blue, the yeast strain Saccharomyces cerevisiae and the animal cells L, NH-3T3, FM3A, CHO, COS, Vero, and HeLa.

The person skilled in the art knows in which way the above DNA has to be inserted in an expression vector. He is also familiar with the fact that the above DNA can be inserted in connection with a DNA coding for another protein and peptide, respectively, so that the above DNA can be expressed in the form of a fusion protein.

A further subject matter of the invention relates to a papilloma virus genome which comprises the above DNA. The expression “papilloma” virus genome” also comprises an incomplete genome, i.e. fragments of a papilloma virus genome, which comprise the above DNA. This may be e.g. a DNA coding for L1 or a portion thereof.

A common process can be used for the provision of the above papilloma virus genome, which comprises the following processing steps:

(a) isolation of the total DNA from a biopsy of epithelial neoplasm,

(b) hybridization of the total DNA of (a) with the above DNA so as to detect a papilloma virus genome included in the total DNA of (a), and

(c) cloning of the total DNA of (a) containing the papilloma virus genome, in a vector and optionally subcloning the resulting clone, all processing steps originating from common DNA recombination technique.

As far as the isolation, hybridization and cloning of cell DNA is concerned, reference is made by way of supplement to Sambrook et al., Molecular Cloning, A Laboratory Manual, second edition, Cold Spring Harbor Laboratory (1989).

The expression “epithelial neoplasm” comprises any neoplasms of epithelium in man and animal. Examples of such neoplasms are warts, condylomas in the genital zone and carcinomas of the skin. The latter are used preferably to isolate the above papilloma virus genome.

The expression “vector” comprises any vectors suitable for cloning chromosomal DNA and extrachromosomal DNA, respectively. Examples of such vectors are cosmids such as pWE15 and Super Cos1, and phages such as λ-phages, e.g. λZAP expression vector, λZAPII vector and λgt10 vector. In the present case, λ-phages are used preferably. The above vectors are known and obtainable from the company of Stratagene.

Papilloma virus genomes according to the invention may be present in integrated form in chromosomal DNA or in extrachromosomal fashion. The person skilled in the art is familiar with processes serving the clarification thereof. He also knows processes serving for finding out the optimum restriction enzymes for cloning the papilloma virus genomes. He will orient himself by genomes of known papilloma viruses. In particular, the person skilled in the art will pay corresponding attention to the above-mentioned HP viruses.

The provision of a papilloma virus genome referred to as VS19-6 is described by way of example. For this purpose, the total DNA is isolated from a biopsy of a squamous cell carcinoma, cleaved by BamHI and separated eletrophoretically in an agarose gel. The agarose gel is then subjected to a blotting method so as to transfer the DNA to a nitrocellulose membrane. It is inserted in a hybridization method in which the DNA of FIG. 1 is used as labeled sample, optionally in combination with a DNA of HP virus 65. Hybridization with the papilloma virus DNA present in the total DNA is obtained.

Moreover, the above total DNA cleaved by BamHI is cloned in a λ-phage. The corresponding clones, i.e. the clones containing the papilloma virus DNA are identified by hybridization with the DNA of FIG. 1, optionally in combination with a DNA of the HP virus 65. The insert of these clones is then subjected to a further cloning in a plasmid vector so as to obtain a clone which contains the papilloma virus genome VS19-6-G. The genome is confirmed by sequencing.

Further papilloma virus genomes are provided analogously. They are designated in accordance with the DNAs used for their provision, namely by: VS200-1-G, VS201-1-G, VS202-8-G, VS203-2-G, VS204-4-G, VS205-1-G, VS206-2-G, VS207-22-G and VS208-1-G, respectively.

A further subject matter of the invention relates to a protein which is coded by the above papilloma virus genome. Such a protein is e.g. a major capsid protein (L1) or a minor capsid protein (L2). An above protein is prepared as usual. The preparation of L1 and L2, respectively, of the papilloma virus genome VS19-6-G is described by way of example. For this purpose, the HP virus 65 related to the DNA of FIG. 1 is used. The full sequence and the position of individual DNA regions coding for proteins are known in connection therewith. These DNAs are identified on the papilloma virus genome VS19-6-G by parallel restriction cleavages of both genomes and subsequent hybridization with various fragments concerning the DNA encoding L1 and L2, respectively. They are confirmed by sequencing. The DNA coding for L1 is referred to as VS19-6-G-L1 DNA and the DNA coding for L2 is referred to as VS19-6-G-L2 DNA.

Furthermore, the DNA coding for L1 and L2, respectively, is inserted in an expression vector. Examples thereof are mentioned above for E. coli, yeast and animal cells. In this connection, reference is made to the vector pGEX-2T as regards the expression in E. coli by way of supplement. Kirnbauer et al., supra. Having inserted the VS19-6-G-L1 DNA and VS19-6-G-L2 DNA, one obtains pGEX-2T-VS19-6-G-L1 and pGEX-2T-VS19-6-G-L2, respectively. After transforming E. coli, these expression vectors express a glutathione S transferase L1 fusion protein and glutathione S transferase L2 fusion protein, respectively. The proteins are purified as usual.

The bacculovirus system and vaccinia virus system, respectively, is mentioned for a further expression of the above DNA encoding L1 and L2, respectively. Expression vectors usable for this purpose are e.g. pEV mod. and pSynwtVI⁻ for the bacculovirus system. Kirnbauer et al., supra. Especially vectors with the vaccinia virus “early” (p7.5k) promoter and “late” (Psynth, p11K) promoter, respectively, have to be mentioned for the vaccinia virus system. Hagensee et al., 1993 Journal of Virology, 67:315-322. The bacculovirus system is preferred in the present case. Having inserted the above DNA encoding L1 and L2, respectively, in pEV mod., one obtains pEVmod.-VS19-6-G-L1 and pEVmod.-VS19-6-G-L2, respectively.

The former expression vector as such or both expression vectors jointly lead to the formation of virus-like particles after infection of SF-9 insect cells. In the former case, such a particle comprises an L1 protein, while in the latter case it contains an L2 protein in addition to an L1 protein.

A virus-like particle of the latter case is also obtained by inserting the above VS19-6-G-L1 and VS19-6-G-L2 DNAs jointly in the expression vector pSynwtVI⁻ and using the resulting pSynwtVI-VS19-6-G-L1/L2 for the infection of SF-9 insect cells. The above virus-like particles are purified as usual. They also represent a subject matter of the invention.

A further subject matter of the invention relates to an antibody directed against an above protein and virus-like particle, respectively. The preparation thereof is made as usual. It is described by way of example for the preparation of an antibody which is directed against a virus-like particle comprising L1 of VS19-6-G. For this purpose, the virus-like particle is injected subcutaneously into BALB/c mice. This injection is repeated at intervals of 3 weeks each. About 2 weeks after the last injection, the serum containing the antibody is isolated and tested as usual.

In a preferred embodiment, the antibody is a monoclonal antibody. For its preparation, spleen cells are removed from the mice after the above fourth injection and fused with myeloma cells as usual. The further cloning also takes place according to known methods.

By means of the present invention it is possible to detect papilloma viruses, particularly in carcinomas of the skin. For this purpose, the DNA according to the invention can be used as such or when comprised by a further DNA. The latter may also be a papilloma virus genome or a portion thereof.

The present invention also enables the provision of formerly unknown papilloma viruses. They are found especially in carcinomas of the skin. In addition, the invention supplies proteins and virus-like particles which originate from these papilloma viruses. Moreover, antibodies are provided which are directed against these proteins and particles, respectively.

The present invention also enables to take diagnostic and therapeutic steps in the case of papilloma virus diseases. Moreover, it supplies the possibility of building up a vaccine against papilloma virus infections. Thus, the present invention represents a break-through in the field of papilloma virus research.

The below examples explain the invention in more detail. The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. The present invention, however is not limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention only, and methods which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

EXAMPLES Example 1 Identification of the Papilloma Virus Genome VS19-6-G

The total DNA is isolated from a biopsy of a squamous cell carcinoma of an immuno-suppressed person. 10 μg of this DNA are cleaved by the restriction enzyme BamHI and separated electrophoretically in a 0.5% agarose gel. At the same time, 10 μg of the above DNA, which was not cleaved, is also separated. The agarose gel is subjected to a blotting method so as to transfer the DNA from the agarose gel to a nitrocellulose membrane. It is employed in a hybridization method in which the above DNA of FIG. 1 is used in combination with the HP virus-65 DNA as ³²P-labeled sample. Hybridization with the blotted DNA is obtained.

The person skilled in the field of DNA recombination technique is familiar with the above methods. Reference is made to Sambrook et al., supra, by way of supplement.

Example 2 Cloning of the Papilloma Virus Genome VS19-6-G

The biopsy DNA obtained from Example 1 is cleaved by the restriction enzyme BamHI. The resulting fragments are used in a ligase reaction in which the dephosphorylated vector λZAP express cleaved by BamHI is also present. The resulting recombinant DNA molecules are packed in bacteriophages, and they are used for infecting bacteria. For these processing steps, the ZAP express vector kit offered by the company of Stratagene is used. The resulting phage plaques are then subjected to a hybridization process which uses the ³²P-labeled DNA of FIG. 1 employed in Example 1 in combination with ³²P-labeled HP virus-65 DNA. Hybridization with corresponding phage plaques is obtained. The BamHI fragments of VS19-6-G are isolated therefrom and used in a further ligase reaction together with a BamHI-cleaved, dephosphorylated plasmid vector, pBluescript. The resulting recombinant DNA molecules are used for transforming bacteria, E. coli XL1-Blue. By restriction cleavages and hybridization with the above DNA samples, respectively, a bacterial clone containing the papilloma virus genome VS19-6-G is identified. The plasmid of this bacterial clone is referred to as pBlue-VS19-6-G.

All references cited within the body of the instant specification are hereby incorporated by reference in their entirety.

30 1 419 DNA Papilloma virus CDS (1)...(417) 1 gga tcc atg cag gat ggt gac atg tgt gat ata gga ttc gga gct tgc 48 Gly Ser Met Gln Asp Gly Asp Met Cys Asp Ile Gly Phe Gly Ala Cys 1 5 10 15 aat ttc agg gca ttt cag caa gat agg tca ggt gtt cct tta gat ata 96 Asn Phe Arg Ala Phe Gln Gln Asp Arg Ser Gly Val Pro Leu Asp Ile 20 25 30 gta gat agt act tgc aag tat cca gac ttt ttg aaa atg aca aaa gac 144 Val Asp Ser Thr Cys Lys Tyr Pro Asp Phe Leu Lys Met Thr Lys Asp 35 40 45 aag tat ggt gat gaa tgc ttc ttt ttt ggt cgt cga gag cag ttg tat 192 Lys Tyr Gly Asp Glu Cys Phe Phe Phe Gly Arg Arg Glu Gln Leu Tyr 50 55 60 gca agg cat tat ttt acc aga gca ggc aca ata ggt gat tct att cca 240 Ala Arg His Tyr Phe Thr Arg Ala Gly Thr Ile Gly Asp Ser Ile Pro 65 70 75 80 acg cca tat cag gaa tct gaa ttt tac aga tct cca cag gat agc cag 288 Thr Pro Tyr Gln Glu Ser Glu Phe Tyr Arg Ser Pro Gln Asp Ser Gln 85 90 95 gct cag aat aat gtg gat tct cac att tat gta gcc act cct agt ggt 336 Ala Gln Asn Asn Val Asp Ser His Ile Tyr Val Ala Thr Pro Ser Gly 100 105 110 tct tta act agc agt gat gct cag ctg ttt aac aga cct tat tgg ctc 384 Ser Leu Thr Ser Ser Asp Ala Gln Leu Phe Asn Arg Pro Tyr Trp Leu 115 120 125 caa aat gct caa ggt acc aat aac gga atg gat cc 419 Gln Asn Ala Gln Gly Thr Asn Asn Gly Met Asp 130 135 2 139 PRT Papilloma virus 2 Gly Ser Met Gln Asp Gly Asp Met Cys Asp Ile Gly Phe Gly Ala Cys 1 5 10 15 Asn Phe Arg Ala Phe Gln Gln Asp Arg Ser Gly Val Pro Leu Asp Ile 20 25 30 Val Asp Ser Thr Cys Lys Tyr Pro Asp Phe Leu Lys Met Thr Lys Asp 35 40 45 Lys Tyr Gly Asp Glu Cys Phe Phe Phe Gly Arg Arg Glu Gln Leu Tyr 50 55 60 Ala Arg His Tyr Phe Thr Arg Ala Gly Thr Ile Gly Asp Ser Ile Pro 65 70 75 80 Thr Pro Tyr Gln Glu Ser Glu Phe Tyr Arg Ser Pro Gln Asp Ser Gln 85 90 95 Ala Gln Asn Asn Val Asp Ser His Ile Tyr Val Ala Thr Pro Ser Gly 100 105 110 Ser Leu Thr Ser Ser Asp Ala Gln Leu Phe Asn Arg Pro Tyr Trp Leu 115 120 125 Gln Asn Ala Gln Gly Thr Asn Asn Gly Met Asp 130 135 3 419 DNA Papilloma virus 3 ggatccattc cgttattggt accttgagca ttttggagcc aataaggtct gttaaacagc 60 tgagcatcac tgctagttaa agaaccacta ggagtggcta cataaatgtg agaatccaca 120 ttattctgag cctggctatc ctgtggagat ctgtaaaatt cagattcctg atatggcgtt 180 ggaatagaat cacctattgt gcctgctctg gtaaaataat gccttgcata caactgctct 240 cgacgaccaa aaaagaagca ttcatcacca tacttgtctt ttgtcatttt caaaaagtct 300 ggatacttgc aagtactatc tactatatct aaaggaacac ctgacctatc ttgctgaaat 360 gccctgaaat tgcaagctcc gaatcctata tcacacatgt caccatcctg catggatcc 419 4 434 DNA Papilloma virus CDS (1)...(432) 4 gga tcc atg gag gac ggt gag atg gca gac ata gga tat ggt aat ctt 48 Gly Ser Met Glu Asp Gly Glu Met Ala Asp Ile Gly Tyr Gly Asn Leu 1 5 10 15 aat ttt aaa gct tta cag gaa aat agg cct gat gtt agt ctt gat att 96 Asn Phe Lys Ala Leu Gln Glu Asn Arg Pro Asp Val Ser Leu Asp Ile 20 25 30 gtc aat gaa acc tgc aaa tat cca gat ttt ttg aag atg caa aat gat 144 Val Asn Glu Thr Cys Lys Tyr Pro Asp Phe Leu Lys Met Gln Asn Asp 35 40 45 gtt tat gga gac tcc tgt ttc ttt ttt gct cgt aga gag caa tgt tat 192 Val Tyr Gly Asp Ser Cys Phe Phe Phe Ala Arg Arg Glu Gln Cys Tyr 50 55 60 gcc aga cac ttt ttt gta aga ggt ggc aac gta ggg gat gac att cct 240 Ala Arg His Phe Phe Val Arg Gly Gly Asn Val Gly Asp Asp Ile Pro 65 70 75 80 ggt gaa caa ata gac gca ggc aca tat aaa aat gat ttt tac att cca 288 Gly Glu Gln Ile Asp Ala Gly Thr Tyr Lys Asn Asp Phe Tyr Ile Pro 85 90 95 gga gca tca ggt cag aca caa aat aaa ata ggt aac tcc atg tat ttc 336 Gly Ala Ser Gly Gln Thr Gln Asn Lys Ile Gly Asn Ser Met Tyr Phe 100 105 110 cca aca gtt agt ggc tca tta gtg tct agt gat gct cag ctg ttt aat 384 Pro Thr Val Ser Gly Ser Leu Val Ser Ser Asp Ala Gln Leu Phe Asn 115 120 125 agg ccc tac tgg ctc caa cgc gca cag ggc cac aac aac ggc gtg gat 432 Arg Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn Asn Gly Val Asp 130 135 140 cc 434 5 144 PRT Papilloma virus 5 Gly Ser Met Glu Asp Gly Glu Met Ala Asp Ile Gly Tyr Gly Asn Leu 1 5 10 15 Asn Phe Lys Ala Leu Gln Glu Asn Arg Pro Asp Val Ser Leu Asp Ile 20 25 30 Val Asn Glu Thr Cys Lys Tyr Pro Asp Phe Leu Lys Met Gln Asn Asp 35 40 45 Val Tyr Gly Asp Ser Cys Phe Phe Phe Ala Arg Arg Glu Gln Cys Tyr 50 55 60 Ala Arg His Phe Phe Val Arg Gly Gly Asn Val Gly Asp Asp Ile Pro 65 70 75 80 Gly Glu Gln Ile Asp Ala Gly Thr Tyr Lys Asn Asp Phe Tyr Ile Pro 85 90 95 Gly Ala Ser Gly Gln Thr Gln Asn Lys Ile Gly Asn Ser Met Tyr Phe 100 105 110 Pro Thr Val Ser Gly Ser Leu Val Ser Ser Asp Ala Gln Leu Phe Asn 115 120 125 Arg Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn Asn Gly Val Asp 130 135 140 6 434 DNA Papilloma virus 6 ggatccacgc cgttgttgtg gccctgtgcg cgttggagcc agtagggcct attaaacagc 60 tgagcatcac tagacactaa tgagccacta actgttggga aatacatgga gttacctatt 120 ttattttgtg tctgacctga tgctcctgga atgtaaaaat catttttata tgtgcctgcg 180 tctatttgtt caccaggaat gtcatcccct acgttgccac ctcttacaaa aaagtgtctg 240 gcataacatt gctctctacg agcaaaaaag aaacaggagt ctccataaac atcattttgc 300 atcttcaaaa aatctggata tttgcaggtt tcattgacaa tatcaagact aacatcaggc 360 ctattttcct gtaaagcttt aaaattaaga ttaccatatc ctatgtctgc catctcaccg 420 tcctccatgg atcc 434 7 410 DNA Papilloma virus CDS (1)...(408) 7 gga tcc cta gag gat ggt gat atg ggt gat ata gga ttt ggg cat gct 48 Gly Ser Leu Glu Asp Gly Asp Met Gly Asp Ile Gly Phe Gly His Ala 1 5 10 15 aat ttt agc cgt tta caa gaa gat aaa gca ggt gtg cca tta gaa tta 96 Asn Phe Ser Arg Leu Gln Glu Asp Lys Ala Gly Val Pro Leu Glu Leu 20 25 30 gtg gac act ttt agt ata tgg cct gac ttt tta cgc atg acc agt gat 144 Val Asp Thr Phe Ser Ile Trp Pro Asp Phe Leu Arg Met Thr Ser Asp 35 40 45 ata tat gga gat gct gtg ttt ttt tgg gga aag cga gaa cat atg ttt 192 Ile Tyr Gly Asp Ala Val Phe Phe Trp Gly Lys Arg Glu His Met Phe 50 55 60 gcc aga cat tta tgg gca aga gct gga act atg ggc gac gct att cca 240 Ala Arg His Leu Trp Ala Arg Ala Gly Thr Met Gly Asp Ala Ile Pro 65 70 75 80 gat aat aat gca gag ttt ttt ctg cat ccc aat ggt gca cct caa aat 288 Asp Asn Asn Ala Glu Phe Phe Leu His Pro Asn Gly Ala Pro Gln Asn 85 90 95 aag tta gcc tca ttt gct tat ttt cca aca cct agt ggt tct ctt aat 336 Lys Leu Ala Ser Phe Ala Tyr Phe Pro Thr Pro Ser Gly Ser Leu Asn 100 105 110 acc agt gat aat caa ttg ttt aat aag ccg tat tgg ttg cga aaa gct 384 Thr Ser Asp Asn Gln Leu Phe Asn Lys Pro Tyr Trp Leu Arg Lys Ala 115 120 125 cag ggc acc aac aat ggg atg gat cc 410 Gln Gly Thr Asn Asn Gly Met Asp 130 135 8 136 PRT Papilloma virus 8 Gly Ser Leu Glu Asp Gly Asp Met Gly Asp Ile Gly Phe Gly His Ala 1 5 10 15 Asn Phe Ser Arg Leu Gln Glu Asp Lys Ala Gly Val Pro Leu Glu Leu 20 25 30 Val Asp Thr Phe Ser Ile Trp Pro Asp Phe Leu Arg Met Thr Ser Asp 35 40 45 Ile Tyr Gly Asp Ala Val Phe Phe Trp Gly Lys Arg Glu His Met Phe 50 55 60 Ala Arg His Leu Trp Ala Arg Ala Gly Thr Met Gly Asp Ala Ile Pro 65 70 75 80 Asp Asn Asn Ala Glu Phe Phe Leu His Pro Asn Gly Ala Pro Gln Asn 85 90 95 Lys Leu Ala Ser Phe Ala Tyr Phe Pro Thr Pro Ser Gly Ser Leu Asn 100 105 110 Thr Ser Asp Asn Gln Leu Phe Asn Lys Pro Tyr Trp Leu Arg Lys Ala 115 120 125 Gln Gly Thr Asn Asn Gly Met Asp 130 135 9 410 DNA Papilloma virus 9 ggatccatcc cattgttggt gccctgagct tttcgcaacc aatacggctt attaaacaat 60 tgattatcac tggtattaag agaaccacta ggtgttggaa aataagcaaa tgaggctaac 120 ttattttgag gtgcaccatt gggatgcaga aaaaactctg cattattatc tggaatagcg 180 tcgcccatag ttccagctct tgcccataaa tgtctggcaa acatatgttc tcgctttccc 240 caaaaaaaca cagcatctcc atatatatca ctggtcatgc gtaaaaagtc aggccatata 300 ctaaaagtgt ccactaattc taatggcaca cctgctttat cttcttgtaa acggctaaaa 360 ttagcatgcc caaatcctat atcacccata tcaccatcct ctagggatcc 410 10 437 DNA Papilloma virus CDS (1)...(435) 10 gga tcc att gag gat gcg gat atg agt gat ata gga ttt gga gct gtg 48 Gly Ser Ile Glu Asp Ala Asp Met Ser Asp Ile Gly Phe Gly Ala Val 1 5 10 15 aat ttt agc act ttc tct gaa agc cgg gct gat gca cct tta gaa tta 96 Asn Phe Ser Thr Phe Ser Glu Ser Arg Ala Asp Ala Pro Leu Glu Leu 20 25 30 atc aat tct att agt aaa tgg cct gat ttt att caa atg tct aag gat 144 Ile Asn Ser Ile Ser Lys Trp Pro Asp Phe Ile Gln Met Ser Lys Asp 35 40 45 att tat ggc gat aga atg ttt ttc ttt gga aaa cgt gag cag atg tat 192 Ile Tyr Gly Asp Arg Met Phe Phe Phe Gly Lys Arg Glu Gln Met Tyr 50 55 60 gca aga cac aca ttt tgt aaa gat ggt gct gtg gga gat gct att cca 240 Ala Arg His Thr Phe Cys Lys Asp Gly Ala Val Gly Asp Ala Ile Pro 65 70 75 80 gaa aat tta aat aat gat gag gat gtt cat cat agg ttt tta tta aat 288 Glu Asn Leu Asn Asn Asp Glu Asp Val His His Arg Phe Leu Leu Asn 85 90 95 cct aag cct gac gca cca cca tat tca aac tta gga aac agt act tac 336 Pro Lys Pro Asp Ala Pro Pro Tyr Ser Asn Leu Gly Asn Ser Thr Tyr 100 105 110 ttt cct atg cca agt ggt tca tta gtt agt agt gaa act caa tta ttt 384 Phe Pro Met Pro Ser Gly Ser Leu Val Ser Ser Glu Thr Gln Leu Phe 115 120 125 aac aga cca ttt tgg cta cat cga gca cag ggc acc aat aac ggc atg 432 Asn Arg Pro Phe Trp Leu His Arg Ala Gln Gly Thr Asn Asn Gly Met 130 135 140 gat cc 437 Asp 145 11 145 PRT Papilloma virus 11 Gly Ser Ile Glu Asp Ala Asp Met Ser Asp Ile Gly Phe Gly Ala Val 1 5 10 15 Asn Phe Ser Thr Phe Ser Glu Ser Arg Ala Asp Ala Pro Leu Glu Leu 20 25 30 Ile Asn Ser Ile Ser Lys Trp Pro Asp Phe Ile Gln Met Ser Lys Asp 35 40 45 Ile Tyr Gly Asp Arg Met Phe Phe Phe Gly Lys Arg Glu Gln Met Tyr 50 55 60 Ala Arg His Thr Phe Cys Lys Asp Gly Ala Val Gly Asp Ala Ile Pro 65 70 75 80 Glu Asn Leu Asn Asn Asp Glu Asp Val His His Arg Phe Leu Leu Asn 85 90 95 Pro Lys Pro Asp Ala Pro Pro Tyr Ser Asn Leu Gly Asn Ser Thr Tyr 100 105 110 Phe Pro Met Pro Ser Gly Ser Leu Val Ser Ser Glu Thr Gln Leu Phe 115 120 125 Asn Arg Pro Phe Trp Leu His Arg Ala Gln Gly Thr Asn Asn Gly Met 130 135 140 Asp 145 12 437 DNA Papilloma virus 12 ggatccatgc cgttattggt gccctgtgct cgatgtagcc aaaatggtct gttaaataat 60 tgagtttcac tactaactaa tgaaccactt ggcataggaa agtaagtact gtttcctaag 120 tttgaatatg gtggtgcgtc aggcttagga tttaataaaa acctatgatg aacatcctca 180 tcattattta aattttctgg aatagcatct cccacagcac catctttaca aaatgtgtgt 240 cttgcataca tctgctcacg ttttccaaag aaaaacattc tatcgccata aatatcctta 300 gacatttgaa taaaatcagg ccatttacta atagaattga ttaattctaa aggtgcatca 360 gcccggcttt cagagaaagt gctaaaattc acagctccaa atcctatatc actcatatcc 420 gcatcctcaa tggatcc 437 13 416 DNA Papilloma virus CDS (1)...(414) 13 gga tcc atg gag gat ggt gaa atg ggc gac ata ggc ttt gga gcc ttt 48 Gly Ser Met Glu Asp Gly Glu Met Gly Asp Ile Gly Phe Gly Ala Phe 1 5 10 15 aat ttt aaa gcc cta cag aaa gat cgt gct ggt gtt agt tta gat tta 96 Asn Phe Lys Ala Leu Gln Lys Asp Arg Ala Gly Val Ser Leu Asp Leu 20 25 30 gtt gat aca ttc agt ata tgg cca gac ttt tta aaa atg act aat gat 144 Val Asp Thr Phe Ser Ile Trp Pro Asp Phe Leu Lys Met Thr Asn Asp 35 40 45 ata tat ggt gac agt atc ttt ttt tat ggt aaa aga gaa cag cta ttt 192 Ile Tyr Gly Asp Ser Ile Phe Phe Tyr Gly Lys Arg Glu Gln Leu Phe 50 55 60 agt aga cac ttg tgg gcc cgc gca gga acg gct gga gat gcc att cca 240 Ser Arg His Leu Trp Ala Arg Ala Gly Thr Ala Gly Asp Ala Ile Pro 65 70 75 80 tct cct gat aac aaa aat cta ata ttt cag ggt gat gat gca gtg cca 288 Ser Pro Asp Asn Lys Asn Leu Ile Phe Gln Gly Asp Asp Ala Val Pro 85 90 95 caa aag act gct ggg tct ttt act tat ttt agt gcc cct agt ggg tca 336 Gln Lys Thr Ala Gly Ser Phe Thr Tyr Phe Ser Ala Pro Ser Gly Ser 100 105 110 tta aca act agt gat tct cag tta ttt aat agg cca tat tgg tta aga 384 Leu Thr Thr Ser Asp Ser Gln Leu Phe Asn Arg Pro Tyr Trp Leu Arg 115 120 125 aga gct caa ggt acc aac aac ggt gtg gat cc 416 Arg Ala Gln Gly Thr Asn Asn Gly Val Asp 130 135 14 138 PRT Papilloma virus 14 Gly Ser Met Glu Asp Gly Glu Met Gly Asp Ile Gly Phe Gly Ala Phe 1 5 10 15 Asn Phe Lys Ala Leu Gln Lys Asp Arg Ala Gly Val Ser Leu Asp Leu 20 25 30 Val Asp Thr Phe Ser Ile Trp Pro Asp Phe Leu Lys Met Thr Asn Asp 35 40 45 Ile Tyr Gly Asp Ser Ile Phe Phe Tyr Gly Lys Arg Glu Gln Leu Phe 50 55 60 Ser Arg His Leu Trp Ala Arg Ala Gly Thr Ala Gly Asp Ala Ile Pro 65 70 75 80 Ser Pro Asp Asn Lys Asn Leu Ile Phe Gln Gly Asp Asp Ala Val Pro 85 90 95 Gln Lys Thr Ala Gly Ser Phe Thr Tyr Phe Ser Ala Pro Ser Gly Ser 100 105 110 Leu Thr Thr Ser Asp Ser Gln Leu Phe Asn Arg Pro Tyr Trp Leu Arg 115 120 125 Arg Ala Gln Gly Thr Asn Asn Gly Val Asp 130 135 15 416 DNA Papilloma virus 15 ggatccacac cgttgttggt accttgagct cttcttaacc aatatggcct attaaataac 60 tgagaatcac tagttgttaa tgacccacta ggggcactaa aataagtaaa agacccagca 120 gtcttttgtg gcactgcatc atcaccctga aatattagat ttttgttatc aggagatgga 180 atggcatctc cagccgttcc tgcgcgggcc cacaagtgtc tactaaatag ctgttctctt 240 ttaccataaa aaaagatact gtcaccatat atatcattag tcatttttaa aaagtctggc 300 catatactga atgtatcaac taaatctaaa ctaacaccag cacgatcttt ctgtagggct 360 ttaaaattaa aggctccaaa gcctatgtcg cccatttcac catcctccat ggatcc 416 16 413 DNA Papilloma virus CDS (1)...(411) 16 gga tcc atg gag gac ggt gag atg agt gat aca ggt ttt ggt gct atg 48 Gly Ser Met Glu Asp Gly Glu Met Ser Asp Thr Gly Phe Gly Ala Met 1 5 10 15 aat ttt gat aat cta tgc gag gac aga gct tca ttt cct tta gac att 96 Asn Phe Asp Asn Leu Cys Glu Asp Arg Ala Ser Phe Pro Leu Asp Ile 20 25 30 ata aat gag acc tcc aag tgg cct gat ttt cta aaa atg aat aaa gat 144 Ile Asn Glu Thr Ser Lys Trp Pro Asp Phe Leu Lys Met Asn Lys Asp 35 40 45 cct tat gga gat cat ata ttt ttc ttt ggt tta cga gag cag tta tat 192 Pro Tyr Gly Asp His Ile Phe Phe Phe Gly Leu Arg Glu Gln Leu Tyr 50 55 60 tcc aga cat cat ggt gct cgg gga gga aaa atg gga gat act att cca 240 Ser Arg His His Gly Ala Arg Gly Gly Lys Met Gly Asp Thr Ile Pro 65 70 75 80 gaa aat aca gca ggc gaa tat tat tat cct cct act gat ggt gct cag 288 Glu Asn Thr Ala Gly Glu Tyr Tyr Tyr Pro Pro Thr Asp Gly Ala Gln 85 90 95 caa aat ata ggt tca cat att tat ttc aat act gtt agt gga tct tta 336 Gln Asn Ile Gly Ser His Ile Tyr Phe Asn Thr Val Ser Gly Ser Leu 100 105 110 aca tct tca gaa act cag ata ttt aat agg cca tat ttt tta caa cgt 384 Thr Ser Ser Glu Thr Gln Ile Phe Asn Arg Pro Tyr Phe Leu Gln Arg 115 120 125 gca cag ggc aca aac aac gga gtg gat cc 413 Ala Gln Gly Thr Asn Asn Gly Val Asp 130 135 17 137 PRT Papilloma virus 17 Gly Ser Met Glu Asp Gly Glu Met Ser Asp Thr Gly Phe Gly Ala Met 1 5 10 15 Asn Phe Asp Asn Leu Cys Glu Asp Arg Ala Ser Phe Pro Leu Asp Ile 20 25 30 Ile Asn Glu Thr Ser Lys Trp Pro Asp Phe Leu Lys Met Asn Lys Asp 35 40 45 Pro Tyr Gly Asp His Ile Phe Phe Phe Gly Leu Arg Glu Gln Leu Tyr 50 55 60 Ser Arg His His Gly Ala Arg Gly Gly Lys Met Gly Asp Thr Ile Pro 65 70 75 80 Glu Asn Thr Ala Gly Glu Tyr Tyr Tyr Pro Pro Thr Asp Gly Ala Gln 85 90 95 Gln Asn Ile Gly Ser His Ile Tyr Phe Asn Thr Val Ser Gly Ser Leu 100 105 110 Thr Ser Ser Glu Thr Gln Ile Phe Asn Arg Pro Tyr Phe Leu Gln Arg 115 120 125 Ala Gln Gly Thr Asn Asn Gly Val Asp 130 135 18 413 DNA Papilloma virus 18 ggatccactc cgttgtttgt gccctgtgca cgttgtaaaa aatatggcct attaaatatc 60 tgagtttctg aagatgttaa agatccacta acagtattga aataaatatg tgaacctata 120 ttttgctgag caccatcagt aggaggataa taatattcgc ctgctgtatt ttctggaata 180 gtatctccca tttttcctcc ccgagcacca tgatgtctgg aatataactg ctctcgtaaa 240 ccaaagaaaa atatatgatc tccataagga tctttattca tttttagaaa atcaggccac 300 ttggaggtct catttataat gtctaaagga aatgaagctc tgtcctcgca tagattatca 360 aaattcatag caccaaaacc tgtatcactc atctcaccgt cctccatgga tcc 413 19 428 DNA Papilloma virus CDS (1)...(426) 19 gga tcc att caa gat ggg gat atg tgc gat att ggc ttt gga gca gcc 48 Gly Ser Ile Gln Asp Gly Asp Met Cys Asp Ile Gly Phe Gly Ala Ala 1 5 10 15 aat ttt aaa gca tta cag caa gat aaa tca ggt gtt cct tta gat att 96 Asn Phe Lys Ala Leu Gln Gln Asp Lys Ser Gly Val Pro Leu Asp Ile 20 25 30 gtt gac agt ata tgt aaa tgg cca gat att att aaa atg gag caa gaa 144 Val Asp Ser Ile Cys Lys Trp Pro Asp Ile Ile Lys Met Glu Gln Glu 35 40 45 ata tat gga gac aga tta ttt ttc ttt act aaa cgt gag caa gct tat 192 Ile Tyr Gly Asp Arg Leu Phe Phe Phe Thr Lys Arg Glu Gln Ala Tyr 50 55 60 gcc agg cat tat ttc gct cgt gca gga att aat ggt gat tct tta cca 240 Ala Arg His Tyr Phe Ala Arg Ala Gly Ile Asn Gly Asp Ser Leu Pro 65 70 75 80 gat gca atg aaa cca gga gaa tat tat ctc tct cct aag ttg gga gat 288 Asp Ala Met Lys Pro Gly Glu Tyr Tyr Leu Ser Pro Lys Leu Gly Asp 85 90 95 gag caa gta ccc cag aaa gac tta gga tcg cat att tat ttt cct aca 336 Glu Gln Val Pro Gln Lys Asp Leu Gly Ser His Ile Tyr Phe Pro Thr 100 105 110 gtt agt ggt tct ttg gtt tct agt gaa aat cag tta ttt aac aga cca 384 Val Ser Gly Ser Leu Val Ser Ser Glu Asn Gln Leu Phe Asn Arg Pro 115 120 125 tat tgg ttg cag aaa tct cag ggc aca aac aac ggc gtg gat 426 Tyr Trp Leu Gln Lys Ser Gln Gly Thr Asn Asn Gly Val Asp 130 135 140 cc 428 20 142 PRT Papilloma virus 20 Gly Ser Ile Gln Asp Gly Asp Met Cys Asp Ile Gly Phe Gly Ala Ala 1 5 10 15 Asn Phe Lys Ala Leu Gln Gln Asp Lys Ser Gly Val Pro Leu Asp Ile 20 25 30 Val Asp Ser Ile Cys Lys Trp Pro Asp Ile Ile Lys Met Glu Gln Glu 35 40 45 Ile Tyr Gly Asp Arg Leu Phe Phe Phe Thr Lys Arg Glu Gln Ala Tyr 50 55 60 Ala Arg His Tyr Phe Ala Arg Ala Gly Ile Asn Gly Asp Ser Leu Pro 65 70 75 80 Asp Ala Met Lys Pro Gly Glu Tyr Tyr Leu Ser Pro Lys Leu Gly Asp 85 90 95 Glu Gln Val Pro Gln Lys Asp Leu Gly Ser His Ile Tyr Phe Pro Thr 100 105 110 Val Ser Gly Ser Leu Val Ser Ser Glu Asn Gln Leu Phe Asn Arg Pro 115 120 125 Tyr Trp Leu Gln Lys Ser Gln Gly Thr Asn Asn Gly Val Asp 130 135 140 21 428 DNA Papilloma virus 21 ggatccacgc cgttgtttgt gccctgagat ttctgcaacc aatatggtct gttaaataac 60 tgattttcac tagaaaccaa agaaccacta actgtaggaa aataaatatg cgatcctaag 120 tctttctggg gtacttgctc atctcccaac ttaggagaga gataatattc tcctggtttc 180 attgcatctg gtaaagaatc accattaatt cctgcacgag cgaaataatg cctggcataa 240 gcttgctcac gtttagtaaa gaaaaataat ctgtctccat atatttcttg ctccatttta 300 ataatatctg gccatttaca tatactgtca acaatatcta aaggaacacc tgatttatct 360 tgctgtaatg ctttaaaatt ggctgctcca aagccaatat cgcacatatc cccatcttga 420 atggatcc 428 22 416 DNA Papilloma virus CDS (1)...(414) 22 gga tcc ctg gaa gat ggt gaa atg gga gat att ggg ttt ggt gca gca 48 Gly Ser Leu Glu Asp Gly Glu Met Gly Asp Ile Gly Phe Gly Ala Ala 1 5 10 15 aat ttt aaa acg tta caa aag gac aga gcc gga gtc agc tta gat tta 96 Asn Phe Lys Thr Leu Gln Lys Asp Arg Ala Gly Val Ser Leu Asp Leu 20 25 30 gta gac act ttt agc att tgg cct gac ttt tta aaa atg act aat gat 144 Val Asp Thr Phe Ser Ile Trp Pro Asp Phe Leu Lys Met Thr Asn Asp 35 40 45 att tac gga gat agt atg ttt ttc ttt gga aaa cgt gag cag ctc ttt 192 Ile Tyr Gly Asp Ser Met Phe Phe Phe Gly Lys Arg Glu Gln Leu Phe 50 55 60 ggc aga cat ctt tgg aca aga gca ggt act ccc ggc gat gca att cct 240 Gly Arg His Leu Trp Thr Arg Ala Gly Thr Pro Gly Asp Ala Ile Pro 65 70 75 80 act cca gaa aat ata aac tta ata ttt cca gct gat gat ggc act agt 288 Thr Pro Glu Asn Ile Asn Leu Ile Phe Pro Ala Asp Asp Gly Thr Ser 85 90 95 caa aag gat gca ggg tct ttc act tac ttt act tca gct agt gga tct 336 Gln Lys Asp Ala Gly Ser Phe Thr Tyr Phe Thr Ser Ala Ser Gly Ser 100 105 110 ctt aat act agc gat tca caa tta ttt aat aga cct tac tgg ctt cga 384 Leu Asn Thr Ser Asp Ser Gln Leu Phe Asn Arg Pro Tyr Trp Leu Arg 115 120 125 cgt gca caa ggc aca aac aat ggc gtg gat cc 416 Arg Ala Gln Gly Thr Asn Asn Gly Val Asp 130 135 23 138 PRT Papilloma virus 23 Gly Ser Leu Glu Asp Gly Glu Met Gly Asp Ile Gly Phe Gly Ala Ala 1 5 10 15 Asn Phe Lys Thr Leu Gln Lys Asp Arg Ala Gly Val Ser Leu Asp Leu 20 25 30 Val Asp Thr Phe Ser Ile Trp Pro Asp Phe Leu Lys Met Thr Asn Asp 35 40 45 Ile Tyr Gly Asp Ser Met Phe Phe Phe Gly Lys Arg Glu Gln Leu Phe 50 55 60 Gly Arg His Leu Trp Thr Arg Ala Gly Thr Pro Gly Asp Ala Ile Pro 65 70 75 80 Thr Pro Glu Asn Ile Asn Leu Ile Phe Pro Ala Asp Asp Gly Thr Ser 85 90 95 Gln Lys Asp Ala Gly Ser Phe Thr Tyr Phe Thr Ser Ala Ser Gly Ser 100 105 110 Leu Asn Thr Ser Asp Ser Gln Leu Phe Asn Arg Pro Tyr Trp Leu Arg 115 120 125 Arg Ala Gln Gly Thr Asn Asn Gly Val Asp 130 135 24 416 DNA Papilloma virus 24 ggatccacgc cattgtttgt gccttgtgca cgtcgaagcc agtaaggtct attaaataat 60 tgtgaatcgc tagtattaag agatccacta gctgaagtaa agtaagtgaa agaccctgca 120 tccttttgac tagtgccatc atcagctgga aatattaagt ttatattttc tggagtagga 180 attgcatcgc cgggagtacc tgctcttgtc caaagatgtc tgccaaagag ctgctcacgt 240 tttccaaaga aaaacatact atctccgtaa atatcattag tcatttttaa aaagtcaggc 300 caaatgctaa aagtgtctac taaatctaag ctgactccgg ctctgtcctt ttgtaacgtt 360 ttaaaatttg ctgcaccaaa cccaatatct cccatttcac catcttccag ggatcc 416 25 425 DNA Papilloma virus CDS (1)...(423) 25 gga tcc cta gag gat ggg gag atg ggt gat ata gga ttt ggt gct gct 48 Gly Ser Leu Glu Asp Gly Glu Met Gly Asp Ile Gly Phe Gly Ala Ala 1 5 10 15 aat ttt gct aag ctt atg caa gat aga gct ggt gta cct ctg gaa tta 96 Asn Phe Ala Lys Leu Met Gln Asp Arg Ala Gly Val Pro Leu Glu Leu 20 25 30 ata gat agt att agt ata tgg cca gat ttt cta aaa atg aca aag gat 144 Ile Asp Ser Ile Ser Ile Trp Pro Asp Phe Leu Lys Met Thr Lys Asp 35 40 45 att tat gga aat gaa gta ttt ttc ttt gga aaa cgc gag caa tgt tat 192 Ile Tyr Gly Asn Glu Val Phe Phe Phe Gly Lys Arg Glu Gln Cys Tyr 50 55 60 gct cgc cat tta ttt gcc aga gct ggt act atg gga gaa cca gta cct 240 Ala Arg His Leu Phe Ala Arg Ala Gly Thr Met Gly Glu Pro Val Pro 65 70 75 80 aat gag act aat gga gta aat ttt ata aat gca aaa cca gga gat cca 288 Asn Glu Thr Asn Gly Val Asn Phe Ile Asn Ala Lys Pro Gly Asp Pro 85 90 95 aat ccc agg agc gct cat atg ggt tct tca gta tac ttt gca aca cct 336 Asn Pro Arg Ser Ala His Met Gly Ser Ser Val Tyr Phe Ala Thr Pro 100 105 110 agt ggc tcc ctt aat acc agt gat tca caa ata ttt aac aga cct tat 384 Ser Gly Ser Leu Asn Thr Ser Asp Ser Gln Ile Phe Asn Arg Pro Tyr 115 120 125 tgg tta cga cgg gct caa gga acg aac aac ggc atg gat cc 425 Trp Leu Arg Arg Ala Gln Gly Thr Asn Asn Gly Met Asp 130 135 140 26 141 PRT Papilloma virus 26 Gly Ser Leu Glu Asp Gly Glu Met Gly Asp Ile Gly Phe Gly Ala Ala 1 5 10 15 Asn Phe Ala Lys Leu Met Gln Asp Arg Ala Gly Val Pro Leu Glu Leu 20 25 30 Ile Asp Ser Ile Ser Ile Trp Pro Asp Phe Leu Lys Met Thr Lys Asp 35 40 45 Ile Tyr Gly Asn Glu Val Phe Phe Phe Gly Lys Arg Glu Gln Cys Tyr 50 55 60 Ala Arg His Leu Phe Ala Arg Ala Gly Thr Met Gly Glu Pro Val Pro 65 70 75 80 Asn Glu Thr Asn Gly Val Asn Phe Ile Asn Ala Lys Pro Gly Asp Pro 85 90 95 Asn Pro Arg Ser Ala His Met Gly Ser Ser Val Tyr Phe Ala Thr Pro 100 105 110 Ser Gly Ser Leu Asn Thr Ser Asp Ser Gln Ile Phe Asn Arg Pro Tyr 115 120 125 Trp Leu Arg Arg Ala Gln Gly Thr Asn Asn Gly Met Asp 130 135 140 27 425 DNA Papilloma virus 27 ggatccatgc cgttgttcgt tccttgagcc cgtcgtaacc aataaggtct gttaaatatt 60 tgtgaatcac tggtattaag ggagccacta ggtgttgcaa agtatactga agaacccata 120 tgagcgctcc tgggatttgg atctcctggt tttgcattta taaaatttac tccattagtc 180 tcattaggta ctggttctcc catagtacca gctctggcaa ataaatggcg agcataacat 240 tgctcgcgtt ttccaaagaa aaatacttca tttccataaa tatcctttgt catttttaga 300 aaatctggcc atatactaat actatctatt aattccagag gtacaccagc tctatcttgc 360 ataagcttag caaaattagc agcaccaaat cctatatcac ccatctcccc atcctctagg 420 gatcc 425 28 398 DNA Papilloma virus CDS (1)...(396) 28 gga tcc ctt gag gat ggg gaa atg ata gat aca ggc tat ggt gcc atg 48 Gly Ser Leu Glu Asp Gly Glu Met Ile Asp Thr Gly Tyr Gly Ala Met 1 5 10 15 gac ttt cgt aca ttg cag gaa acc aaa agt gag gta cca cta gat att 96 Asp Phe Arg Thr Leu Gln Glu Thr Lys Ser Glu Val Pro Leu Asp Ile 20 25 30 tgc caa tcc gtg tgt aaa tat cct gat tat ttg cag atg tct gct gat 144 Cys Gln Ser Val Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ser Ala Asp 35 40 45 gta tat ggg gac agt atg ttt ttt tgt ttg cgc aag gaa cag ttg ttt 192 Val Tyr Gly Asp Ser Met Phe Phe Cys Leu Arg Lys Glu Gln Leu Phe 50 55 60 gcc agg cac ttt tgg aat aga ggt ggc atg gtg ggc gac aca ata cct 240 Ala Arg His Phe Trp Asn Arg Gly Gly Met Val Gly Asp Thr Ile Pro 65 70 75 80 tca gag tta tat att aaa ggc acg gat ata cgt gag cgt cct ggt act 288 Ser Glu Leu Tyr Ile Lys Gly Thr Asp Ile Arg Glu Arg Pro Gly Thr 85 90 95 cat gta tat tcc cct tcc cca agt ggc tct atg gtc tct tct gat tcc 336 His Val Tyr Ser Pro Ser Pro Ser Gly Ser Met Val Ser Ser Asp Ser 100 105 110 cag ttg ttt aat aag ccc tat tgg ttg cat aag gcc caa ggc cac aat 384 Gln Leu Phe Asn Lys Pro Tyr Trp Leu His Lys Ala Gln Gly His Asn 115 120 125 aac ggg atg gat cc 398 Asn Gly Met Asp 130 29 132 PRT Papilloma virus 29 Gly Ser Leu Glu Asp Gly Glu Met Ile Asp Thr Gly Tyr Gly Ala Met 1 5 10 15 Asp Phe Arg Thr Leu Gln Glu Thr Lys Ser Glu Val Pro Leu Asp Ile 20 25 30 Cys Gln Ser Val Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ser Ala Asp 35 40 45 Val Tyr Gly Asp Ser Met Phe Phe Cys Leu Arg Lys Glu Gln Leu Phe 50 55 60 Ala Arg His Phe Trp Asn Arg Gly Gly Met Val Gly Asp Thr Ile Pro 65 70 75 80 Ser Glu Leu Tyr Ile Lys Gly Thr Asp Ile Arg Glu Arg Pro Gly Thr 85 90 95 His Val Tyr Ser Pro Ser Pro Ser Gly Ser Met Val Ser Ser Asp Ser 100 105 110 Gln Leu Phe Asn Lys Pro Tyr Trp Leu His Lys Ala Gln Gly His Asn 115 120 125 Asn Gly Met Asp 130 30 398 DNA Papilloma virus 30 ggatccatcc cgttattgtg gccttgggcc ttatgcaacc aatagggctt attaaacaac 60 tgggaatcag aagagaccat agagccactt ggggaagggg aatatacatg agtaccagga 120 cgctcacgta tatccgtgcc tttaatatat aactctgaag gtattgtgtc gcccaccatg 180 ccacctctat tccaaaagtg cctggcaaac aactgttcct tgcgcaaaca aaaaaacata 240 ctgtccccat atacatcagc agacatctgc aaataatcag gatatttaca cacggattgg 300 caaatatcta gtggtacctc acttttggtt tcctgcaatg tacgaaagtc catggcacca 360 tagcctgtat ctatcatttc cccatcctca agggatcc 398 

What is claimed is:
 1. An isolated polynucleotide comprising: (a) a nucleotide sequence encoding the peptide of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; (b) a nucleotide sequence hybridizing to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; or (c) the complement of (a) or (b); wherein the polynucleotide has a homology of at least 90% to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.
 2. An isolated polynucleotide encoding a peptide of a papilloma virus major capsid protein, wherein the said polynucleotide has been obtained using the following steps: (a) incubating total DNA isolated from a biopsy of epithelial neoplasm with a nucleic acid having at least a portion of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, under a condition that allows hybridization of a polynucleotide derived from a papilloma virus genome included in the total DNA to said nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; and (b) identifying and isolating a polynucleotide that hybridizes to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10 in step (a); wherein the polynucleotide has a homology of at least 90% to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.
 3. An isolated polynucleotide, comprising (a) a nucleic acid encoding a peptide comprising the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, or (b) the complement of (a).
 4. An isolated polynucleotide, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ I) NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, or the complement thereof.
 5. A plasmid comprising the polynucleotide of claim 1 or
 2. 6. A plasmid comprising the polynucleotide of claim
 3. 7. An expression vector comprising the polynucleotide of claim 1 or
 2. 8. An expression vector comprising the polynucleotide of claim
 3. 9. A host cell comprising the plasmid of claim
 5. 10. A host cell comprising the plasmid of claim
 6. 11. A host cell comprising the expression vector of claim
 7. 12. A host cell comprising the expression vector of claim
 8. 13. A method of producing a peptide of a papilloma virus major capsid protein, comprising cultivating the host cell of claim 11 under suitable conditions.
 14. A method of producing a peptide of a papilloma virus major capsid proteins comprising cultivating the host cell of claim 12 under suitable conditions.
 15. A method of detecting a papilloma virus DNA, comprising: (a) hybridizing under stringent conditions at least a portion of the polynucleotide of claim 1, 2, 3, or 4 to a DNA sample; and (b) identifying papilloma virus in said DNA sample by detecting a hybridization signal.
 16. A virus-like particle comprising a polypeptide encoded by the polynucleotide of claim 1 or
 2. 17. The virus-like particle of claim 16, further comprising a papilloma virus minor capsid protein.
 18. A virus-like particle comprising a polypeptide encoded by the polynucleotide of claim
 3. 19. The virus-like particle of claim 18, further comprising a papilloma virus minor capsid protein.
 20. A composition comprising the virus-like particle of claim 16 as reagent for diagnosis, treatment and/or vaccination.
 21. A composition comprising the virus-like particle of claim 17 as reagent for diagnosis, treatment and/or vaccination.
 22. A composition comprising the virus-like particle of claim 18 as reagent for diagnosis, treatment and/or vaccination.
 23. A composition comprising the virus-like particle of claim 19 as reagent for diagnosis, treatment and/or vaccination.
 24. A composition comprising the polynucleotide of claim 1, 2, 3, or 4 as reagent for diagnosis and a diagnostically acceptable carrier.
 25. A pharmaceutical composition comprising the virus-like particle according to claim 16, and a pharmaceutically acceptable carrier.
 26. A pharmaceutical composition comprising the virus-like particle according to claim 17, and a pharmaceutically acceptable carrier.
 27. A pharmaceutical composition comprising the virus-like particle according to claim 18, and a pharmaceutically acceptable carrier.
 28. A pharmaceutical composition comprising the virus-like particle according to claim 19, and a pharmaceutically acceptable carrier.
 29. A method of producing a papilloma virus genome, comprising: (a) incubating total DNA isolated from a biopsy of epithelial neoplasm with a nucleic acid having at least a portion of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID) NO:5, SEQ ID NO:6, SEQ ID) NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, under a condition that allows hybridization of a polynucleotide derived from a papilloma virus genome included in the total DNA to said nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10; and (b) identifying and isolating a polynucleotide that hybridizes to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10 in step (a).
 30. The method of claim 29, wherein the polynucleotide has a homology of at least 90% to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.
 31. A method of vaccinating a subject in need against papilloma virus, comprising administering to said subject the composition of claim
 29. 